Broad Institute and UPenn-linked cardiovascular disease drug developer Verve priced an upscaled initial public offering above its range.

GV and Novo-backed cardiovascular disease drug developer Verve priced an upscaled initial public offering above its range.

SoftBank Vision Fund 2 co-led a series B round for immunotherapy developer Umoja Biopharma with Cormorant Asset Management.

Umoja Biopharma, based on research at Purdue University and Seattle Children’s Research Institute, has picked up a series B co-led by SoftBank Vision Fund 2.

The Johnson & Johnson, GSK and AstraZeneca-backed drug developer raised the cash in a Patient Square Capital-led round that took its total funding beyond $200m.

GV has participated in a $41.9m series B extension for the birth control delivery service, which increased the round's size to $92.9m.

UCL Technology Fund has participated in a $145m round that will allow Apollo Therapeutics to advance assets into the clinic and open a US office.

Maryland Momentum Fund and VTC Innovation Fund have both contributed to a series A round for Veralox Therapeutics, which is focusing on diseases with unmet needs.

Bitwise Asset Management completed a $70m round backed by Coinbase at a $500m-plus valuation, while luxury goods wholesaler Joor raised $46m to take its overall funding to $81m.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.